MX2021007437A - Formas deuteradas y derivados de volinanserina. - Google Patents

Formas deuteradas y derivados de volinanserina.

Info

Publication number
MX2021007437A
MX2021007437A MX2021007437A MX2021007437A MX2021007437A MX 2021007437 A MX2021007437 A MX 2021007437A MX 2021007437 A MX2021007437 A MX 2021007437A MX 2021007437 A MX2021007437 A MX 2021007437A MX 2021007437 A MX2021007437 A MX 2021007437A
Authority
MX
Mexico
Prior art keywords
disorder
compounds
volinanserin
deuterated forms
disease
Prior art date
Application number
MX2021007437A
Other languages
English (en)
Inventor
Scott L Harbeson
Scott Weintraub
Original Assignee
Terran Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Terran Biosciences Inc filed Critical Terran Biosciences Inc
Publication of MX2021007437A publication Critical patent/MX2021007437A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
    • C07D211/14—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70571—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Zoology (AREA)
  • Psychiatry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Cell Biology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se describen formas deuteradas de volinanserina de acuerdo con la Fórmula estructural (I) y sus sales farmacéuticamente aceptables, composiciones farmacéuticas que contienen estos compuestos y métodos de tratamiento o prevención utilizando estos compuestos o composiciones farmacéuticas. (ver fórmula I) Los compuestos son útiles para tratar o prevenir una enfermedad o afección seleccionada de psicosis, esquizofrenia, trastorno esquizoafectivo, enfermedad de Parkinson, demencia con cuerpos de Lewy, trastorno del sueño (incluido el insomnio), agitación, trastorno del estado de ánimo (incluida la depresión), trastorno tromboembólico, autismo y trastorno hiperactivo por déficit de atención.
MX2021007437A 2018-12-21 2019-12-20 Formas deuteradas y derivados de volinanserina. MX2021007437A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862784056P 2018-12-21 2018-12-21
PCT/US2019/067885 WO2020132461A1 (en) 2018-12-21 2019-12-20 Deuterated forms and derivatives of volinanserin

Publications (1)

Publication Number Publication Date
MX2021007437A true MX2021007437A (es) 2021-09-08

Family

ID=71101633

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021007437A MX2021007437A (es) 2018-12-21 2019-12-20 Formas deuteradas y derivados de volinanserina.

Country Status (14)

Country Link
US (1) US20220106272A1 (es)
EP (1) EP3897507A4 (es)
JP (1) JP7548906B2 (es)
KR (1) KR20210124976A (es)
CN (1) CN113747870A (es)
AU (1) AU2019403391A1 (es)
BR (1) BR112021012082A8 (es)
CA (1) CA3124399A1 (es)
EA (1) EA202191731A1 (es)
IL (1) IL284201A (es)
MX (1) MX2021007437A (es)
SG (1) SG11202106692UA (es)
WO (1) WO2020132461A1 (es)
ZA (1) ZA202104656B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115057774A (zh) * 2022-04-28 2022-09-16 北京绮一舟新材料技术有限公司 一种α-氘代羧酸衍生物类化合物及氘代药物的合成方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5140416B2 (ja) * 2004-06-21 2013-02-06 ユニヴァーシティー オブ ミシシッピ 望ましい化学的官能基を有する抗がん及び抗原虫ジヒドロアーテミシニン及びジヒドロアーテミシテンダイマー
US8198305B2 (en) * 2007-04-13 2012-06-12 Concert Pharmaceuticals Inc. 1,2-benzisoxazol-3-yl compounds
US20110190345A1 (en) 2007-08-06 2011-08-04 Huszar Sarah L Treatment of Psychosis with a 5HT2A Antagonist and a Metabotropic Glutamate Receptor Agonist or Potentiator
WO2009094210A1 (en) * 2008-01-22 2009-07-30 Concert Pharmaceuticals Inc. Vandetanib derivatives
US20130197032A1 (en) * 2010-09-20 2013-08-01 A. Carlsson Research Ab Phenylpiperidine compounds for the treatment of neurological and psychiatric disorders
EP2714624B1 (en) * 2011-05-23 2017-12-27 Sanofi Process for the preparation of deuterated compounds containing n-alkyl groups
SI2720989T1 (sl) * 2011-06-20 2016-11-30 H. Lundbeck A/S Devterirani 1-piperazino-3-fenil indani za zdravljenje shizofrenije
EP2968469A4 (en) * 2013-03-15 2016-08-31 Longevity Biotech Inc PEPTIDES COMPRISING NON-ENDOGENIC AMINO ACIDS AND METHODS OF MAKING AND USING SAME
WO2018023009A1 (en) * 2016-07-29 2018-02-01 Concert Pharmaceuticals, Inc. Deuterated lurasidone

Also Published As

Publication number Publication date
CN113747870A (zh) 2021-12-03
KR20210124976A (ko) 2021-10-15
WO2020132461A1 (en) 2020-06-25
BR112021012082A8 (pt) 2023-03-21
EA202191731A1 (ru) 2021-10-28
JP2022515156A (ja) 2022-02-17
CA3124399A1 (en) 2020-06-25
IL284201A (en) 2021-08-31
EP3897507A1 (en) 2021-10-27
BR112021012082A2 (pt) 2021-08-31
JP7548906B2 (ja) 2024-09-10
EP3897507A4 (en) 2022-09-14
AU2019403391A1 (en) 2021-08-05
US20220106272A1 (en) 2022-04-07
ZA202104656B (en) 2022-10-26
SG11202106692UA (en) 2021-07-29

Similar Documents

Publication Publication Date Title
PH12016502095A1 (en) Isoindoline-1-one derivatives as cholinergic muscarinic m1 receptor positive alloesteric modulator activity for the treatment of alzheimers disease
MX2022016276A (es) Nuevos profarmacos de catecolamina para uso en el tratamiento de la enfermedad de parkinson.
TW201129562A (en) Iminothiadiazine dioxide compounds as BACE inhibitors, compositions, and their use
MX2022000709A (es) Regimenes de tratamiento con dexmedetomidina no sedante.
MX366855B (es) Compuestos perfluorados de 5,6-dihidro-4h-1,3-oxazin-2-amina como inhibidores de beta-secretasa y metodos de uso.
IN2014DN03206A (es)
TN2018000322A1 (en) Allosteric modulators of nicotinic acetylcholine receptors
TW200801029A (en) Glucopyranosyl-substituted benzonitrile derivatives, pharmaceutical compositions containing such compounds, their use and process for their manufacture
GEP201706608B (en) 1 - arylcarbonyl - 4 - oxy – piperidine compounds useful for the treatment of neurodegenerative diseases
MX2019015371A (es) Derivados de dihidro-pirrolo-piridina.
MX2019007101A (es) Derivados de oxazina como inhibidores de beta secretasa y metodos de uso.
MX2019007104A (es) Derivados de dioxido de 1,4-tiazina y dioxido de 1,2,4-tiadiazina como inhibidores de beta-secretasa y metodos de uso.
TW201613890A (en) Pyridine derivatives as muscarinic M1 receptor positive allosteric modulators
PH12019502334A1 (en) Benzoazepine analogs as inhibiting agents for bruton's tyrosine kinase
PH12018502457B1 (en) Treatment for parkinson's disease
MX2009009466A (es) Compuestos triciclicos de utilidad en el tratamiento de trastornos del hierro.
MX2022003177A (es) Derivados de piridazin-3(2h)-ona fusionados con azol.
MX2017009824A (es) Triazoles sustituidos y metodos relacionados a estos.
MX2019007100A (es) Derivados de tiazina y oxazina biciclicos como inhibidores de beta-secretasa y metodos de uso.
MX2019007102A (es) Derivados de tiazina como inhibidores de beta-secretasa y metodos de uso.
PH12021550043A1 (en) Use of riluzole prodrugs to treat alzheimer's disease
MX2017001603A (es) Derivados de piperazina como moduladores de los receptores x del higado.
MX2017005715A (es) Potentes moduladores de gamma-secretasa.
MX2021007437A (es) Formas deuteradas y derivados de volinanserina.
MX2019008601A (es) Un derivado de oxazina base libre en forma cristalina.